Anti-Inflammatory Effects of GLP-1R Activation in the Retina.
Humans
Glucagon-Like Peptide-1 Receptor
Incretins
/ therapeutic use
Diabetes Mellitus, Type 2
/ drug therapy
Hypoglycemic Agents
/ pharmacology
Endothelial Cells
Glucagon-Like Peptide 1
/ pharmacology
Retina
Glucose
/ therapeutic use
Retinal Diseases
Inflammation
Anti-Inflammatory Agents
/ pharmacology
GLP-1
GLP-1R
GLP-1RAs
age-related macular degeneration
diabetic retinopathy
endothelial cells
glaucoma
retinal ganglion cells
retinal pigment epithelial cells
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
17 Oct 2022
17 Oct 2022
Historique:
received:
06
09
2022
revised:
12
10
2022
accepted:
13
10
2022
entrez:
27
10
2022
pubmed:
28
10
2022
medline:
29
10
2022
Statut:
epublish
Résumé
Glucagon-like peptide-1 (GLP-1) is an incretin hormone, mainly produced by enteroendocrine L cells, which participates in the regulation of glucose homeostasis, and in reduction in body weight by promoting satiety. Actions of GLP-1 are mediated by activation of its receptor GLP-1R, which is widely expressed in several tissues including the retina. The effects of GLP-1R activation are useful in the management of type 2 diabetes mellitus (T2DM). In addition, the activation of GLP-1R has anti-inflammatory effects in several organs, suggesting that it may be also useful in the treatment of inflammatory diseases. Inflammation is a common element in the pathogenesis of several ocular diseases, and the protective effects of treatment with GLP-1 emerged also in retinal diseases. In this review we highlight the anti-inflammatory effects of GLP-1R activation in the retina. Firstly, we summarized the pathogenic role of inflammation in ocular diseases. Then, we described the pleiotropic effects of GLP-1R activation on the cellular components of the retina which are mainly involved in the pathogenesis of inflammatory retinal diseases: the retinal ganglion cells, retinal pigment epithelial cells and endothelial cells.
Identifiants
pubmed: 36293281
pii: ijms232012428
doi: 10.3390/ijms232012428
pmc: PMC9604172
pii:
doi:
Substances chimiques
Glucagon-Like Peptide-1 Receptor
0
Incretins
0
Hypoglycemic Agents
0
Glucagon-Like Peptide 1
89750-14-1
Glucose
IY9XDZ35W2
Anti-Inflammatory Agents
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Prog Retin Eye Res. 2011 Sep;30(5):343-58
pubmed: 21635964
Br J Pharmacol. 2020 Aug;177(15):3389-3402
pubmed: 32232832
Diabetes Metab. 2015 Jun;41(3):183-94
pubmed: 25794703
Diabetologia. 2017 Nov;60(11):2285-2298
pubmed: 28779212
Curr Med Chem. 2013;20(26):3241-50
pubmed: 23745549
Eye (Lond). 2019 Dec;33(12):1842-1851
pubmed: 31227789
Mol Neurodegener. 2016 Apr 06;11:26
pubmed: 27048300
BMJ Open Diabetes Res Care. 2018 Jan 30;6(1):e000475
pubmed: 29449951
Sci Rep. 2019 Oct 31;9(1):15742
pubmed: 31673100
PLoS One. 2016 Dec 12;11(12):e0167853
pubmed: 27942008
Am J Pathol. 2002 Feb;160(2):501-9
pubmed: 11839570
Annu Rev Biochem. 1998;67:199-225
pubmed: 9759488
Front Pharmacol. 2019 Nov 29;10:1363
pubmed: 31849644
Mol Metab. 2021 Apr;46:101102
pubmed: 33068776
Nat Rev Mol Cell Biol. 2011 Jan;12(1):9-14
pubmed: 21179058
Lancet. 2011 Apr 16;377(9774):1367-77
pubmed: 21453963
Annu Rev Nutr. 2014;34:237-60
pubmed: 24819325
Pharmacol Rep. 2019 Feb;71(1):175-182
pubmed: 30554037
Graefes Arch Clin Exp Ophthalmol. 2008 Dec;246(12):1665-70
pubmed: 18682976
Graefes Arch Clin Exp Ophthalmol. 2009 May;247(5):699-706
pubmed: 19084986
JCI Insight. 2017 Jul 20;2(14):
pubmed: 28724805
Clin Ther. 2011 May;33(5):511-27
pubmed: 21665040
Exp Eye Res. 2014 Oct;127:104-16
pubmed: 24910901
Autoimmun Rev. 2017 Dec;16(12):1254-1264
pubmed: 29037906
Diabetes. 2011 Jan;60(1):9-16
pubmed: 21193734
Front Endocrinol (Lausanne). 2021 Apr 14;12:668012
pubmed: 33935978
Int J Mol Sci. 2022 Apr 19;23(9):
pubmed: 35562891
J Clin Invest. 2011 Apr;121(4):1429-44
pubmed: 21383504
Rev Endocr Metab Disord. 2021 Dec;22(4):1171-1188
pubmed: 34228302
Br J Pharmacol. 2022 Feb;179(4):715-726
pubmed: 34519040
Diabetes Obes Metab. 2018 Sep;20(9):2304-2308
pubmed: 29707863
Mol Cell Endocrinol. 2014 Feb 15;382(2):938-49
pubmed: 24275181
Prog Retin Eye Res. 2014 Nov;43:17-75
pubmed: 25038518
Invest Ophthalmol Vis Sci. 2016 May 1;57(6):2584-92
pubmed: 27163772
Prog Retin Eye Res. 2014 May;40:53-93
pubmed: 24583621
Antioxidants (Basel). 2020 Sep 10;9(9):
pubmed: 32927585
Br J Ophthalmol. 1975 Nov;59(11):649-56
pubmed: 1203221
Lancet. 2018 Sep 29;392(10153):1147-1159
pubmed: 30303083
J Neurochem. 2002 Mar;80(5):771-9
pubmed: 11948240
J Clin Biochem Nutr. 2016 Nov;59(3):174-181
pubmed: 27895384
Exp Eye Res. 2016 Jan;142:71-5
pubmed: 26675403
Diabetes Obes Metab. 2011 Apr;13(4):302-12
pubmed: 21205117
Peptides. 2017 Jun;92:1-8
pubmed: 28450048
J Neurosci. 2012 May 2;32(18):6391-410
pubmed: 22553043
J Clin Endocrinol Metab. 2020 Apr 1;105(4):
pubmed: 31589290
Cell Metab. 2016 Jul 12;24(1):15-30
pubmed: 27345422
Proc Natl Acad Sci U S A. 2016 May 10;113(19):E2655-64
pubmed: 27114552
Pharmacol Rev. 2016 Oct;68(4):954-1013
pubmed: 27630114
Int J Biochem Cell Biol. 2015 Feb;59:41-51
pubmed: 25483438
Peptides. 2018 Feb;100:123-126
pubmed: 28807775
Am J Pathol. 2019 Oct;189(10):2061-2076
pubmed: 31361992
Cell Metab. 2018 Apr 3;27(4):740-756
pubmed: 29617641
Ophthalmic Res. 2020;63(4):404-412
pubmed: 31865348
Transl Res. 2021 Oct;236:52-71
pubmed: 34051364
Pharmacol Rep. 2013;65(4):884-90
pubmed: 24145082
Front Pharmacol. 2021 Sep 17;12:718902
pubmed: 34603029
Front Pharmacol. 2021 Jul 28;12:727870
pubmed: 34393803
Graefes Arch Clin Exp Ophthalmol. 2007 Jul;245(7):1009-18
pubmed: 17186260
Cutan Ocul Toxicol. 2021 Sep;40(3):175-186
pubmed: 34275397
Hum Cell. 2022 Jul;35(4):995-1004
pubmed: 35583801
Lancet. 2006 Nov 11;368(9548):1696-705
pubmed: 17098089
FEBS J. 2022 Apr;289(8):2337-2361
pubmed: 34478598
Int J Med Sci. 2017 Sep 19;14(12):1203-1212
pubmed: 29104476
Cell. 2007 Dec 14;131(6):1164-78
pubmed: 18083105
Prog Retin Eye Res. 2016 Mar;51:1-40
pubmed: 26113209
Arch Biochem Biophys. 2007 Jun 15;462(2):245-53
pubmed: 17475204
Acta Diabetol. 2017 Oct;54(10):933-941
pubmed: 28748377
J Diabetes Complications. 2022 Aug;36(8):108255
pubmed: 35817678
Indian J Endocrinol Metab. 2013 May;17(3):413-21
pubmed: 23869296
Cell Rep. 2020 Nov 3;33(5):108271
pubmed: 33147455
Front Neurosci. 2019 Oct 18;13:1112
pubmed: 31680842
Int J Endocrinol. 2020 Feb 29;2020:1762164
pubmed: 32190049
Mech Ageing Dev. 2020 Apr;187:111215
pubmed: 32084459
Int J Mol Sci. 2020 Jan 25;21(3):
pubmed: 31991717
Diabetes. 2016 Jan;65(1):172-87
pubmed: 26384381
Pharmacol Res. 2022 Aug;182:106320
pubmed: 35738455
Front Pharmacol. 2021 Feb 12;11:589114
pubmed: 33679385
Invest Ophthalmol Vis Sci. 2016 Apr;57(4):1807-15
pubmed: 27082295
Front Endocrinol (Lausanne). 2021 Aug 23;12:721135
pubmed: 34497589
J Biol Chem. 2003 Aug 1;278(31):29278-87
pubmed: 12740394
Nat Med. 2018 Jul;24(7):931-938
pubmed: 29892066
Diabetes Ther. 2016 Sep;7(3):483-96
pubmed: 27262995
Neuron. 2012 Jul 12;75(1):26-39
pubmed: 22794258
Diabetes. 2010 Jul;59(7):1780-8
pubmed: 20424229
Eur J Pharmacol. 2017 Oct 5;812:64-72
pubmed: 28688914
J Clin Endocrinol Metab. 2016 Feb;101(2):748-56
pubmed: 26695864
JCI Insight. 2021 Dec 8;6(23):
pubmed: 34673570
Oxid Med Cell Longev. 2021 Dec 13;2021:9247947
pubmed: 34938383
Peptides. 2012 Sep;37(1):25-31
pubmed: 22727809
Invest Ophthalmol Vis Sci. 2011 Jan 05;52(1):278-85
pubmed: 20688733
Diabetes. 2017 Jun;66(6):1453-1460
pubmed: 28533296
Mediators Inflamm. 2016;2016:3094642
pubmed: 27110066
Adv Clin Exp Med. 2021 May;30(5):555-561
pubmed: 33984196
Exp Eye Res. 2021 Jul;208:108624
pubmed: 34022175
Semin Immunopathol. 2012 Jan;34(1):73-91
pubmed: 21805322
Prog Retin Eye Res. 2004 Jan;23(1):53-89
pubmed: 14766317
PLoS One. 2011 Mar 31;6(3):e18305
pubmed: 21483783
Diabetes Obes Metab. 2021 Aug;23(8):1806-1822
pubmed: 33830637
Am J Pathol. 2020 May;190(5):1080-1094
pubmed: 32354571
Endocrinol Metab (Seoul). 2017 Sep;32(3):316-325
pubmed: 28956360
Biomed Pharmacother. 2018 Jan;97:1061-1065
pubmed: 29136785
Curr Mol Med. 2010 Dec;10(9):802-23
pubmed: 21091424
Mediators Inflamm. 2013;2013:975032
pubmed: 24307763
Neuropharmacology. 2019 Jul 15;153:1-12
pubmed: 31015047
Int J Inflam. 2013;2013:724648
pubmed: 24109539
Biochem Pharmacol. 2018 Oct;156:406-419
pubmed: 30195733
Biol Pharm Bull. 2015;38(5):694-702
pubmed: 25947915
Diabetologia. 2010 Dec;53(12):2656-66
pubmed: 20835858
Neurotherapeutics. 2021 Jul;18(3):1834-1848
pubmed: 34260042
Biomed Pharmacother. 2019 Mar;111:1315-1325
pubmed: 30841445
Physiol Rev. 2005 Jul;85(3):845-81
pubmed: 15987797
Peptides. 2018 Jul;105:7-13
pubmed: 29746877
Biochem J. 1990 Feb 15;266(1):213-9
pubmed: 2106874
Mol Vis. 2014 Nov 05;20:1557-68
pubmed: 25489228
Diabetologia. 2018 Nov;61(11):2412-2421
pubmed: 30097694
Am J Physiol Heart Circ Physiol. 2016 Nov 1;311(5):H1214-H1224
pubmed: 27638877
Adv Clin Exp Med. 2015 May-Jun;24(3):531-5
pubmed: 26467145
Exp Eye Res. 2016 Oct;151:203-11
pubmed: 27212443
Exp Diabetes Res. 2007;2007:43603
pubmed: 17641741
Diabetologia. 2011 Nov;54(11):2745-54
pubmed: 21744074